Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
August 25, 2022 07:00 ET
|
Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
August 24, 2022 16:01 ET
|
PDS Biotechnology Corporation
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK,...
Pharmacogenomics Market Size is projected to reach USD 11.79 Billion by 2030, growing at a CAGR of 8.47%: Straits Research
August 23, 2022 15:35 ET
|
Straits Research
New York, USA, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The global pharmacogenomics market is expected to grow due to the constantly rising need for treating fatal diseases like cancer and increasing...
Florida Cancer Specialists & Research Institute Appoints New Members to Senior Management
August 22, 2022 13:30 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome the following members to its senior management team. Jon...
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
August 22, 2022 09:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and...
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET
|
POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...
Arvinas Announces Changes to its Board of Directors
August 18, 2022 16:01 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
August 17, 2022 12:38 ET
|
Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Precipio Launches New 1-Step Technology for all HemeScreen Assays
August 16, 2022 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
August 16, 2022 01:05 ET
|
Myriad Genetics, Inc.
Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, FranceLatest expansions represent Myriad’s commitment to growing international lab partner program SALT LAKE CITY, Aug....